EUVIMED · CrossrefZeitschrift
Annals of Hepatology
ISSN 1665-2681 · Elsevier BV
Neueste Artikel
Investigation of non-invasive tests for fibrosis diagnosis and prognostication of events in metabolic dysfunction-associated steatotic liver disease: A prospective study cohort
Prediction of incident overt hepatic encephalopathy using individual and composite measures of minimal hepatic encephalopathy: the PrO-MHE study
Aligning MASLD care with the United Nations Sustainable Development Goals: A call for integrated policy and clinical action
Artificial intelligence in Latin American hepatology: current evidence, implementation barriers, and strategic priorities
Hepatocellular carcinoma surveillance in MASLD: from cirrhosis-based screening to personalized risk stratification
A cohort study of physical activity, gut microbiota, serum metabolites, and the risk of steatotic liver disease
Clinically significant portal hypertension rather than ALBI grade predicts prognosis in advanced hepatocellular carcinoma
Evolution and impact of sarcopenia and myosteatosis in the context of liver transplantation
Hepatic hydrothorax: Time to rethink the treatment paradigm?
Timing in Acute Variceal Bleeding: Have We Really Figured It Out?
From concentrated output to regional capacity: the next step for Latin American hepatology research
Acute-on-chronic liver failure: A global multisociety consensus on definitions
Endoscopy timing in managing acute esophagogastric variceal bleeding: a multicenter retrospective study
Large esophageal varices predict hepatocellular carcinoma in newly diagnosed cirrhosis: insights from machine learning and propensity score analysis
Treatment outcomes in hepatic hydrothorax: A propensity score–matched survival analysis
Pharmacotherapy for MASLD: current evidence and challenges in clinical practice
From availability to governance: a continuum model for the adoption of artificial intelligence in clinical medicine
Long-Term Outcomes and Trends in Simultaneous Liver-Kidney Transplantation: A Multicenter Cohort Study
Is FIB-4 the right tool for screening for liver fibrosis?
ALEH position statement on the management of hepatitis B virus infection 2025
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among primary care providers in the four most populous U.S. cities
Nationwide analysis on the impact of the organization of care on the outcomes of perihilar cholangiocarcinoma
The global academic hepatology capacity index (GAHCI): a multi-source assessment reveals profound disparities across Latin America
Making metabolic dysfunction-associated steatotic liver disease medicines affordable: Lessons from hepatitis C
Comment on “Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab”
Development and validation of a prediction model for acute kidney injury in cirrhosis with normal serum creatinine levels
Reframing chronic hepatitis B care through digital twin modelling
Comment on “drug-induced liver injury: A real-world pharmacovigilance study using the FDA adverse event reporting system database (2004–2024)”
Beyond the impact factor: What readers and authors value in scientific journals
Beyond portal pressure reduction: Interpreting the survival benefit of statin add-on therapy in portal hypertension
EUVIMED